# Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

> **NCT03799224** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Stem Cell Transplant Complications
- Relapse Leukemia
- Refractory Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** mBU/CY and ATG
- **DRUG:** mBU/CY

## Key facts

- **NCT ID:** NCT03799224
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2019-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799224, "Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03799224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*